{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:06:55Z","timestamp":1784714815705,"version":"3.55.0"},"reference-count":79,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Bleeding is one of the most common and feared complications after coronary angiography and percutaneous coronary intervention (PCI). It is associated with longer hospital stays, higher mortality, and worse clinical outcomes. As the number of patients at high bleeding risk (HBR) continues to grow, preventing bleeding has become an important part of PCI management. This practical review summarizes current evidence on how to assess bleeding risk and reduce bleeding before, during, and after PCI. Several tools, including the BARC classification, ARC-HBR criteria, PRECISE-DAPT, and DAPT scores, help identify patients who may benefit from tailored treatment. Current strategies include the use of radial access, optimized anticoagulation, appropriate selection of antiplatelet therapy, newer-generation drug-eluting stents, and shorter durations of dual antiplatelet therapy in selected HBR patients. We also discuss the management of patients with atrial fibrillation requiring oral anticoagulation, as well as those with anemia or thrombocytopenia. Although significant progress has been made, several questions remain unanswered, particularly regarding transfusion thresholds, antithrombotic therapy in complex patients, and the best balance between bleeding and ischemic risks. Ongoing clinical trials are expected to provide further evidence and help improve the management of patients undergoing PCI.<\/jats:p>","DOI":"10.3390\/jcm15145729","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T09:20:39Z","timestamp":1784712039000},"page":"5729","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Percutaneous Coronary Interventions: Bleeding Risk Assessment and Management"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9659-0396","authenticated-orcid":false,"given":"Adil","family":"Salihu","sequence":"first","affiliation":[{"name":"Department of Cardiology, Lausanne University Hospital, University of Lausanne, Rue du Bugnon 46, 1011 Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5524-5844","authenticated-orcid":false,"given":"David","family":"Meier","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Lausanne University Hospital, University of Lausanne, Rue du Bugnon 46, 1011 Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thabo","family":"Mahendiran","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Lausanne University Hospital, University of Lausanne, Rue du Bugnon 46, 1011 Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelia","family":"Zimmerli","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Lausanne University Hospital, University of Lausanne, Rue du Bugnon 46, 1011 Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremie","family":"Buri","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Lausanne University Hospital, University of Lausanne, Rue du Bugnon 46, 1011 Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Klopfenstein","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Lausanne University Hospital, University of Lausanne, Rue du Bugnon 46, 1011 Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Scala","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Lausanne University Hospital, University of Lausanne, Rue du Bugnon 46, 1011 Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Fournier","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Lausanne University Hospital, University of Lausanne, Rue du Bugnon 46, 1011 Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1016\/j.jacc.2015.03.567","article-title":"Bleeding avoidance strategies during percutaneous coronary interventions","volume":"65","author":"Singh","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.jacc.2020.06.085","article-title":"Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel","volume":"76","author":"Capodanno","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jacc.2020.05.031","article-title":"Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI","volume":"76","author":"Dalgaard","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1001\/jama.2013.1556","article-title":"Association Between Bleeding Events and In-hospital Mortality After Percutaneous Coronary Intervention","volume":"309","author":"Chhatriwalla","year":"2013","journal-title":"JAMA-J. Am. Med. Assoc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.jacc.2014.01.069","article-title":"The prognostic value of bleeding academic research consortium (BARC)-defined bleeding complications in ST-segment elevation myocardial infarction: A comparison with the TIMI (Thrombolysis In Myocardial Infarction), GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries), and ISTH (International Society on Thrombosis and Haemostasis) bleeding classifications","volume":"63","author":"Kikkert","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1093\/eurheartj\/ehz372","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention: A consensus document from the Academic Research Consortium for High Bleeding Risk","volume":"40","author":"Urban","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: A pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/j.jacc.2025.08.040","article-title":"Personalized or Standard Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: The PARTHENOPE Randomized Trial","volume":"86","author":"Piccolo","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.jacc.2024.11.009","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"85","author":"Rao","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1161\/CIRCULATIONAHA.122.061527","article-title":"Effects on Mortality and Major Bleeding of Radial Versus Femoral Artery Access for Coronary Angiography or Percutaneous Coronary Intervention: Meta-Analysis of Individual Patient Data From 7 Multicenter Randomized Clinical Trials","volume":"146","author":"Gargiulo","year":"2022","journal-title":"Circulation"},{"key":"ref_14","first-page":"176","article-title":"Distal Trans-radial Access Compared to Conventional Trans-radial Access in Coronary Interventions: A Meta-analysis","volume":"21","author":"Talha","year":"2022","journal-title":"Crit. Pathw. Cardiol."},{"key":"ref_15","first-page":"857","article-title":"Transulnar versus transradial access for coronary angiography or percutaneous coronary intervention: A meta-analysis of randomized controlled trials","volume":"87","author":"Dahal","year":"2016","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamacardio.2022.3399","article-title":"Routine Ultrasonography Guidance for Femoral Vascular Access for Cardiac Procedures: The UNIVERSAL Randomized Clinical Trial","volume":"7","author":"Jolly","year":"2022","journal-title":"JAMA Cardiol."},{"key":"ref_17","first-page":"CD014594","article-title":"Ultrasound-guided versus anatomic landmark-guided percutaneous femoral artery access","volume":"3","author":"Strauss","year":"2025","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e025666","DOI":"10.1161\/JAHA.122.025666","article-title":"Femoral Vascular Closure Devices and Bleeding, Hemostasis, and Ambulation Following Percutaneous Coronary Intervention","volume":"12","author":"Huang","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/jamainternmed.2019.2431","article-title":"Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant","volume":"179","author":"Douketis","year":"2019","journal-title":"JAMA Intern. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1056\/NEJMoa1501035","article-title":"Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation","volume":"373","author":"Douketis","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_21","first-page":"1177","article-title":"Peri-Procedural Management of Oral Anticoagulant Therapy in Patients Undergoing Percutaneous Coronary Intervention: Insights from the PERSEO Multicenter Registry","volume":"106","author":"Rigattieri","year":"2025","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jacc.2020.09.011","article-title":"2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Solution Set Oversight Committee","volume":"77","author":"Kumbhani","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ijcard.2016.08.089","article-title":"Meta-analysis of uninterrupted as compared to interrupted oral anticoagulation with or without bridging in patients undergoing coronary angiography with or without percutaneous coronary intervention","volume":"223","author":"Kowalewski","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_24","first-page":"255","article-title":"SCAI expert consensus update on best practices in the cardiac catheterization laboratory: This statement was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), and the Heart Rhythm Society (HRS) in April 2021","volume":"98","author":"Naidu","year":"2021","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_25","first-page":"1371","article-title":"Uninterrupted Direct-Acting Oral Anticoagulation in Patients Undergoing Transradial Percutaneous Coronary Procedures: The DOAC-NOSTOP","volume":"106","author":"Chiarito","year":"2025","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1093\/eurheartj\/ehac270","article-title":"2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery","volume":"43","author":"Halvorsen","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e2134322","DOI":"10.1001\/jamanetworkopen.2021.34322","article-title":"Assessment of Pretreatment With Oral P2Y12 Inhibitors and Cardiovascular and Bleeding Outcomes in Patients With Non-ST Elevation Acute Coronary Syndromes: A Systematic Review and Meta-analysis","volume":"4","author":"Dawson","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJMoa1407024","article-title":"Prehospital ticagrelor in ST-segment elevation myocardial infarction","volume":"371","author":"Montalescot","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1001\/jamacardio.2026.1128","article-title":"Efficacy and Safety of Prasugrel, Ticagrelor, or Clopidogrel After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis","volume":"11","author":"Maqsood","year":"2026","journal-title":"JAMA Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/hrt.2010.195438","article-title":"Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: A systematic review and meta-analysis","volume":"97","author":"Huber","year":"2011","journal-title":"Heart"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Revelly, E., Scala, E., Rosner, L., Rancati, V., Gunga, Z., Kirsch, M., Ltaief, Z., Rusca, M., Bechtold, X., and Alberio, L. (2023). How to Solve the Conundrum of Heparin-Induced Thrombocytopenia during Cardiopulmonary Bypass. J. Clin. Med., 12.","DOI":"10.3390\/jcm12030786"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e1275","DOI":"10.4244\/EIJV11I11A249","article-title":"Impact of bivalirudin on post-procedural epicardial blood flow, risk of stent thrombosis and mortality after percutaneous coronary intervention","volume":"11","author":"Fiedler","year":"2016","journal-title":"Eurointervention"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/S0140-6736(22)01999-7","article-title":"Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A randomised trial","volume":"400","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/eurheartj\/ehv434","article-title":"The comparative efficacy of bivalirudin is markedly attenuated by use of radial access: Insights from Blue Cross Blue Shield of Michigan Cardiovascular Consortium","volume":"37","author":"Perdoncin","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa1706443","article-title":"Bivalirudin versus Heparin Monotherapy in Myocardial Infarction","volume":"377","author":"Erlinge","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1016\/j.jcin.2016.09.020","article-title":"Use and Effectiveness of Bivalirudin Versus Unfractionated Heparin for Percutaneous Coronary Intervention Among Patients With ST-Segment Elevation Myocardial Infarction in the United States","volume":"9","author":"Secemsky","year":"2016","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1161\/CIRCULATIONAHA.123.063946","article-title":"Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials","volume":"148","author":"Bikdeli","year":"2023","journal-title":"Circulation"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"131168","DOI":"10.1016\/j.ijcard.2023.131168","article-title":"Safety of routine protamine in the reversal of heparin in percutaneous coronary intervention: A systematic review and meta-analysis","volume":"388","author":"Lee","year":"2023","journal-title":"Int. J. Cardiol."},{"key":"ref_39","first-page":"337","article-title":"Antithrombotic therapy for secondary prevention in patients with acute coronary syndromes treated with percutaneous coronary intervention: Options for personalization to reduce bleeding or ischaemic risks","volume":"15","author":"Gorog","year":"2026","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/eurheartj\/ehac706","article-title":"Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: A meta-analysis of randomized trials","volume":"44","author":"Costa","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa2507980","article-title":"Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes","volume":"393","author":"Guimaraes","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"n1332","DOI":"10.1136\/bmj.n1332","article-title":"P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: Individual patient level meta-analysis of randomised controlled trials","volume":"373","author":"Valgimigli","year":"2021","journal-title":"BMJ"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/S0140-6736(24)00473-2","article-title":"Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT) a randomised, placebo-controlled, double-blind clinical trial","volume":"403","author":"Ge","year":"2024","journal-title":"Lancet"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1161\/CIRCULATIONAHA.123.066943","article-title":"Stopping Aspirin Within 1 Month After Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome: The T-PASS Randomized Noninferiority Trial","volume":"149","author":"Hong","year":"2024","journal-title":"Circulation"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e773","DOI":"10.4244\/EIJ-D-26-00421","article-title":"Ticagrelor monotherapy versus dual antiplatelet therapy after primary percutaneous coronary intervention: One-year outcomes of the pilot STOP-IMH randomised trial","volume":"22","author":"Yosofi","year":"2026","journal-title":"Eurointervention"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","article-title":"Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): A randomised, open-label, multicentre trial","volume":"390","author":"Sibbing","year":"2017","journal-title":"Lancet"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/eurheartj\/ehx175","article-title":"Benefit of switching dual antiplatelet therapy after acute coronary syndrome: The TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study","volume":"38","author":"Cuisset","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/S0140-6736(26)00422-8","article-title":"Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention: 10-year follow-up of the HOST-EXAM trial","volume":"407","author":"Kang","year":"2026","journal-title":"Lancet"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0140-6736(25)00449-0","article-title":"Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): A randomised, open-label, multicentre trial","volume":"405","author":"Choi","year":"2025","journal-title":"Lancet"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/S0140-6736(21)00533-X","article-title":"Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: A systematic review and meta-analysis","volume":"397","author":"Galli","year":"2021","journal-title":"Lancet"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ahj.2024.10.004","article-title":"Dual antiplatelet therapy duration and stent type in patients with high bleeding risk: A systematic review and network meta-analysis","volume":"279","author":"Saito","year":"2025","journal-title":"Am. Heart J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s11239-021-02628-8","article-title":"Comparison of biodegradable and newer generation durable polymer drug-eluting stents with short-term dual antiplatelet therapy: A systematic review and Bayesian network meta-analysis of randomized trials comprising of 43,875 patients","volume":"53","author":"Chong","year":"2022","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_57","first-page":"893","article-title":"Percutaneous coronary intervention with drug-coated balloon-only strategy in stable coronary artery disease and in acute coronary syndromes: An all-comers registry study","volume":"93","author":"Uskela","year":"2019","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Panuccio, G., Carabetta, N., Sportelli, M., Tartaglione, G., Mashayekhi, K., Brilakis, E.S., Leistner, D.M., Sorrentino, S., Abdelwahed, Y., and Landmesser, U. (2026). Association of DAPT duration with bleeding and ischemic outcomes after percutaneous coronary intervention with drug-coated balloons: A meta-analysis. Clin. Res. Cardiol.","DOI":"10.1007\/s00392-026-02934-2"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.jcin.2020.02.043","article-title":"Drug-Coated Balloons for Coronary Artery Disease: Third Report of the International DCB Consensus Group","volume":"13","author":"Jeger","year":"2020","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/europace\/euz259","article-title":"Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: Meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials","volume":"22","author":"Potpara","year":"2020","journal-title":"Europace"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/heartjnl-2019-315963","article-title":"P2Y(12) inhibitors with oral anticoagulation for percutaneous coronary intervention with atrial fibrillation: A systematic review and meta-analysis","volume":"106","author":"Lupercio","year":"2020","journal-title":"Heart"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jcin.2025.01.451","article-title":"Cangrelor During Percutaneous Coronary Intervention in Patients With Cardiogenic Shock or Cardiac Arrest","volume":"18","author":"Emilsson","year":"2025","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.mayocp.2022.02.016","article-title":"Newer P2Y(12) Inhibitors vs Clopidogrel in Acute Myocardial Infarction With Cardiac Arrest or Cardiogenic Shock: A Systematic Review and Meta-analysis","volume":"97","author":"Patlolla","year":"2022","journal-title":"Mayo Clin. Proc."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e1309","DOI":"10.4244\/EIJ-D-24-00203","article-title":"Cangrelor versus crushed ticagrelor in patients with acute myocardial infarction and cardiogenic shock: Rationale and design of the randomised, double-blind DAPT-SHOCK-AMI trial","volume":"20","author":"Motovska","year":"2024","journal-title":"Eurointervention"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/MCA.0000000000000311","article-title":"Transition strategies from cangrelor to oral platelet P2Y12 receptor antagonists","volume":"27","author":"Schneider","year":"2016","journal-title":"Coron. Artery Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13054-025-05277-y","article-title":"Potent P2Y(12) inhibitors in patients with acute myocardial infarction and cardiogenic shock","volume":"29","author":"Jo","year":"2025","journal-title":"Crit. Care"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"154771","DOI":"10.1016\/j.jcrc.2024.154771","article-title":"Bleeding complications, coagulation disorders, and their management in acute myocardial infarction-related cardiogenic shock rescued by veno-arterial ECMO: A retrospective cohort study","volume":"82","author":"Masi","year":"2024","journal-title":"J. Crit. Care"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1053\/j.jvca.2023.08.153","article-title":"Evaluation of Cangrelor Use After Percutaneous Coronary Intervention in Patients With Mechanical Circulatory Support","volume":"37","author":"Pluenneke","year":"2023","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.amjcard.2016.05.059","article-title":"Meta-Analysis of the Prognostic Impact of Anemia in Patients Undergoing Percutaneous Coronary Intervention","volume":"118","author":"Kwok","year":"2016","journal-title":"Am. J. Cardiol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.7326\/ANNALS-25-00706","article-title":"Red Cell Transfusion in Acute Myocardial Infarction: AABB International Clinical Practice Guidelines","volume":"178","author":"Pagano","year":"2025","journal-title":"Ann. Intern. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.7326\/M24-0571","article-title":"Effect of Four Hemoglobin Transfusion Threshold Strategies in Patients With Acute Myocardial Infarction and Anemia: A Target Trial Emulation Using MINT Trial Data","volume":"177","author":"Portela","year":"2024","journal-title":"Ann. Intern. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/jama.2021.0135","article-title":"Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia The REALITY Randomized Clinical Trial","volume":"325","author":"Ducrocq","year":"2021","journal-title":"Jama-J. Am. Med. Assoc."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.amjcard.2011.06.014","article-title":"Conservative Versus Liberal Red Cell Transfusion in Acute Myocardial Infarction (the CRIT Randomized Pilot Study)","volume":"108","author":"Cooper","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.ahj.2013.03.001","article-title":"Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease","volume":"165","author":"Carson","year":"2013","journal-title":"Am. Heart J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1001\/jama.2023.12914","article-title":"Red Blood Cell Transfusion: 2023 AABB International Guidelines","volume":"330","author":"Carson","year":"2023","journal-title":"JAMA"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMra1612789","article-title":"Indications for and Adverse Effects of Red-Cell Transfusion","volume":"377","author":"Carson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1001\/jama.2011.592","article-title":"Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: A randomized controlled trial","volume":"305","author":"Najjar","year":"2011","journal-title":"JAMA"},{"key":"ref_79","first-page":"895","article-title":"SCAI expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (Endorsed by the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencionista)","volume":"87","author":"Iliescu","year":"2016","journal-title":"Catheter. Cardiovasc. Interv."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5729\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T09:57:10Z","timestamp":1784714230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/14\/5729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":79,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15145729"],"URL":"https:\/\/doi.org\/10.3390\/jcm15145729","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]}}}